Roundtable
Roundtable
Advertisement
Katy Beckermann, MD, PhDRenal Cell Carcinoma | June 17, 2024
The panel concludes with the applications, challenges, and future prospects of belzutifan in treating advanced kidney cancer.
View More
Katy Beckermann, MD, PhDRenal Cell Carcinoma | June 17, 2024
The panel explores the latest research in rare subtypes of kidney cancer, emphasizing the need for biology-driven trials.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | June 17, 2024
The panel emphasizes the need to decrease RCC overtreatment and to identify cured patients in the adjuvant setting.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | June 17, 2024
The panel offers evolving strategies for managing treatment durations and holds for patients on IO/TKI and PD-1 regimens.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | June 17, 2024
The panel highlights the potential practice-changing impact of subcutaneous PD-1 agents for kidney cancer treatment.Dr.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | June 17, 2024
The panel focuses on the final OS analysis from the JAVELIN Renal 101 trial and the challenges of combining IOs with TKIs.
Katie S. Murray, DO, MSUrothelial Carcinoma | June 9, 2024
The panel offers concluding thoughts on selection criteria for lymph node dissection in patients with low-grade UTUC.
Katie S. Murray, DO, MSUrothelial Carcinoma | June 9, 2024
The panel dissects a longitudinal follow-up of a multicenter study of UGN-101 as well as other 2024 AUA meeting data.
Katie S. Murray, DO, MSUrothelial Carcinoma | June 9, 2024
The panel considers how to best treat patients with low-grade UTUC who experience disease recurrence post-surgery.
Katie S. Murray, DO, MSUrothelial Carcinoma | June 9, 2024
The panel highlights nephron-sparing approaches as well as current treatment pathways for low-grade UTUC.
Katie S. Murray, DO, MSUrothelial Carcinoma | June 9, 2024
The panel provides a disease state overview of low-grade UTUC, including considerations for diagnosis, staging, and grading.
Katie S. Murray, DO, MSUrothelial Carcinoma | June 9, 2024
The panel engages in a discussion related to risk stratification in UTUC, including identification of high-risk patients.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel shared their excitement for the road ahead in kidney cancer.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel addressed different dosing scenarios and shared tips on how to counsel patients on their treatment.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel shared their thoughts on quality of life data presented from the LITESPARK-005 trial of belzutifan.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel discussed the impact of a subcutaneous formulation of nivolumab.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel discussed the role of SBRT and some exciting studies like SAMURAI.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel discussed CheckMate 9ER, which assessed quality of life outcomes in patients receiving cabozantinib/nivolumab.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel shared their thoughts on the 8-year follow-up data from CheckMate 214.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel discussed two studies that assessed adjuvant treatment: KEYNOTE-564 and CheckMate 914.
Advertisement
Advertisement
Advertisement